Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study.

Although between-regimen differences were not statistically significant, mepolizumab 300 mg showed a numerical trend toward earlier glucocorticoid sparing (e.g., higher GC-free rates and fewer patients on higher GC doses at intermediate visits), which may reflect its preferential use in patients with systemic disease and its intended role in systemic disease management ( 6 , 7 ).

also in 723 other papers

In the mepolizumab 100 mg group, GC-free status increased from 6/16 (37.5%) to 7/12 (58.3%), although this within-group change did not reach statistical significance ( Supplementary Table 1 ).

also in 75,281 other papers